Key result
Genetic and clinical profiling of 120 Indian boys with Duchenne muscular dystrophy established a genetic diagnosis in 95% of cases, revealing a significant 4-year diagnostic lag from symptom onset.
Answers are grounded in this paper and cite their sources.
This editorial highlights the significant diagnostic lag in Indian boys with Duchenne muscular dystrophy and emphasizes the need for early genetic diagnosis to improve clinical care and assess eligibility for emerging gene therapies.
Duchenne muscular dystrophy (DMD) is the most common and lethal neuromuscular disorder of childhood-onset affecting 1 in 3500–5000 boys.[1] The progressive muscular weakness in boys with DMD leads to loss of ambulation by 11–13 years of age and death in late teens. Despite >100 years of the first description by French neurologist Guillaume Benjamin Amand Duchenne de Boulogne in the year 1860, the disease remains incurable till now, although steroids and supportive care have significantly increased the longevity and quality of life of these children.[2] We read the manuscript “Duchenne muscular dystrophy: Genetic and clinical profile in the population of Rajasthan, India” with great interest.[3] The authors described the genotype and phenotype of 120 boys with DMD from Rajasthan, India. The authors reported symptom onset at 3.2 years and diagnostic confirmation at 7.2 years of age. A genetic diagnosis could be established in 110 (95%) cases, with MLPA followed by next-generation sequencing (NGS) approach. In 10 genetically undiagnosed cases, muscle biopsy could confirm the diagnosis in six patients. Certain important facts emerge from this manuscript, first is the time lag in genetic confirmation of the diagnosis in boys with DMD. Although boys with DMD had symptoms in early childhood at 3.2 ± 1.3 years in this study, the genetic confirmation was achieved at 7.2 ± 2.4 years of age. The considerable diagnostic lag was also present in 17% of cases with a positive family history. The delay in genetic confirmation keeps the parents anxious, in a denial state, and hampers DMD-directed clinical care. Rehabilitation with physiotherapy, orthotics, and initiation of steroid therapy is often considerably delayed because of diagnostic lag. Improving parental and physician awareness is vital for timely referral and initiation of clinical care. Early rehabilitation and initiation of steroids keep the muscle strength preserved for a longer duration and maintain ambulation for a longer period. In this prospective series of boys with DMD, a genetic diagnosis could be established in 110 (95%) boys with MLPA, followed by NGS-based approach. Though muscle biopsy is the gold standard for diagnosis of DMD, the facilities for immunohistochemistry are available at fewer centers. MLPA can diagnose approximately 70% of cases with DMD, and 30% cases require sanger sequencing for smaller variants.[4] The genetic diagnostic approach with MLPA and NGS is highly effective and lesser invasive.[4] A genetic diagnosis should be confirmed even in subjects with a positive muscle biopsy for primary prevention, prenatal diagnosis, and to assess eligibility for newer therapies. The authors reported the age of loss of ambulation was nine years, and wheel-chair dependency was 11.2 years in their cohort. Most of these children had deletions in distal exons. A detailed analysis of functional abilities in boys with DMD and disease course should be documented to make such assumptions. In addition, the phenotype of DMD correlates well with the reading frame rule. The out-of-frame mutations are associated with a severe DMD phenotype, and in-frame mutations are associated with a less severe phenotype of Becker muscular dystrophy. In this cohort of Indian boys with DMD, the loss of ambulation was earlier in comparison to their western counterparts, possibly related to more severe phenotype, delayed initiation of steroids, and lack of standard supportive care.[5] The dystrophin gene is among the largest genes with 79 exons and 78 introns, and it is highly susceptible for mutations. The major hot spots for mutations are located at exon 43–55 and exon 2–20.[6] In the cohort of 116 boys with genetically confirmed DMD, 64 (70%) had a mutation in the distal hotspot, and 15 (16%) had a mutation in the proximal hotspot region. In addition, 6 (5.4%) boys had a nonsense mutation, 35 (31%) and 25 (22.7%) had involvement of exon 51 and 50. With the current advancement in the gene therapies for DMD, according to this information, 5% Indian children are eligible for Ataluren, and approximately 15%–20% are amenable to exon skipping therapy with Eteplirsen (for exon 51), golodirsen and Viltolarsen for exon 53.[6] With the availability of genetic diagnosis in boys with DMD, the emphasis should be to improve the clinical care and rehabilitation services for these children. Standard physiotherapy, orthotic devices, and steroid therapy should be available to boys with DMD.[7] Though significant advancements have been made with exon skipping therapy, but these drugs are less likely to be available to Indian children with DMD shortly. Indian children with DMD should receive standard of care therapy to improve muscle strength and reduced respiratory and cardiac complications. Financial support and sponsorship Not applicable. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Suthar et al. (2023) conducted a letter in Duchenne muscular dystrophy (n=120). Genetic and clinical profiling was evaluated on Establishment of genetic diagnosis. Genetic and clinical profiling of 120 Indian boys with Duchenne muscular dystrophy established a genetic diagnosis in 95% of cases, revealing a significant 4-year diagnostic lag from symptom onset.
Synapse has enriched 10 related papers. Consider them for comparative context: